PZRXQ (PhaseRx) FCF Margin %: 0.00% (As of Sep. 2017)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is PhaseRx FCF Margin %?

PhaseRx PZRXQ -99.00% FCF Margin % is 0.00% as of Sep. 2017.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. PhaseRx's Free Cash Flow for the three months ended in Sep. 2017 was $-2.57 Mil. PhaseRx's Revenue for the three months ended in Sep. 2017 was $0.00 Mil. Therefore, PhaseRx's FCF Margin % for the quarter that ended in Sep. 2017 was 0.00%.

As of today, PhaseRx's current FCF Yield % is 0.00%.

The historical rank and industry rank for PhaseRx's FCF Margin % or its related term are showing as below:


PZRXQ's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -82.65
* Ranked among companies with meaningful FCF Margin % only.

PhaseRx FCF Margin % Related Terms

PhaseRx FCF Margin % Historical Data

* Premium members only.

The historical data trend for PhaseRx's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PhaseRx FCF Margin % Chart

PhaseRx Annual Data
Trend Dec14 Dec15 Dec16
FCF Margin %
-409.50 -1,625.07 0.00

PhaseRx Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PZRXQ vs NSPX, HSTC, PRGBQ: FCF Margin % Comparison

For the Biotechnology subindustry, PhaseRx's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PhaseRx FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PhaseRx's FCF Margin % distribution charts can be found below:

* The bar in red indicates where PhaseRx's FCF Margin % falls into.


PhaseRx FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

PhaseRx's FCF Margin for the fiscal year that ended in Dec. 2016 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2016 )/Revenue (A: Dec. 2016 )
=-9.982/0
= %

PhaseRx's FCF Margin for the quarter that ended in Sep. 2017 is calculated as

FCF Margin=Free Cash Flow (Q: Sep. 2017 )/Revenue (Q: Sep. 2017 )
=-2.572/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 0.00% mean?
PhaseRx (PZRXQ) has a FCF Margin % of 0.00% as of Sep. 2017. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on PhaseRx and its competitors.
Is PhaseRx's FCF Margin % too high?
PhaseRx's current FCF Margin % is 0.00%.
How does PhaseRx's FCF Margin % compare to NSPX and HSTC?
PhaseRx's FCF Margin % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on PhaseRx and its competitors. PhaseRx's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PhaseRx stock overvalued right now?
PhaseRx (PZRXQ) has a current FCF Margin % of 0.00%. The current FCF Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For PhaseRx (PZRXQ), the current FCF Margin % is 0.00% as of Sep. 2017. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PhaseRx Business Description

Address 410 West Harrison Street, Suite 300, Seattle, WA, USA, 98119
PhaseRx Inc is a biopharmaceutical company. It is developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy, or i-ERT. The approach is enabled by proprietary Hybrid messenger RNA, or mRNA, Technology platform, which allows synthesis of the missing enzyme inside the cell. The product portfolio targets the three urea cycle disorders ornithine transcarbamylase deficiency, or OTCD, argininosuccinate lyase deficiency, or ASL deficiency, and argininosuccinate synthetase deficiency, or ASS1 deficiency.